Summary
The importance of individualizing the dosage of potent drugs in order to maximize their therapeutic effectiveness and safety is generally accepted. Whenever possible the dosage of a drug should be “titrated” directly in each patient against the intensity of its therapeutic or toxic actions. Unfortunately, for many drugs convenient clinical yardsticks of the intensity of their pharmacologic effects are lacking. Determination of the serum concentration of such compounds can help to guide adjustment of dosage during their therapeutic use. By measuring the serum level of drugs one bypasses the largest source of individual differences in doseeffect relationships — the pharmacokinetic variation between subjects. However, the relationship between the serum concentration of a drug and the intensity of its pharmacodynamic action is influenced by many other factors, which must always be considered in interpretation of serum levels. Therapeutic decisions should never be based solely on the serum concentration of a compound, nor can such measurements ever substitute for careful medical observation and judgement.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ariëns, E.J.: Drug levels in the target tissue and effect. Clin. Pharmacol. Ther.16, 155–175 (1974)
Atkinson, A.J., Jr.: Individualization of anti-convulsant therapy. Med. Clin. North Amer.58, 1037–1049 (1974)
Azarnoff, D.L. (ed.): Implications of blood level assays of therapeutic agents. Clin. Pharmacol. Ther.16, 129–288 (1974)
Bigger, J.T., Jr., Schmidt, D.H., Kutt, M.: Relationship between the plasma level of diphenylhydantoin sodium and its cardiac anti-arrhythmic effects. Circulation38, 363–374 (1968)
Blackwell, B.: Patient compliance. New Engl. J. Med.289, 249–252 (1973)
Butler, V.P., Jr., Lindenbaum, J.: Serum digitalis measurements in the assessment of digitalis resistance and sensitivity. Amer. J. Med.58, 460–469 (1975)
Davies, D.S., Prichard, B.N.C. (ed.): Biological effects of drugs in relation to their plasma concentration. London: Macmillan 1973
Duhme, D.W., Greenblatt, D.J., Koch-Weser, J.: Reduction of digoxin toxicity associated with measurement of serum levels. Ann. intern. Med.80, 516–519 (1974)
Gottschalk, L.A., Merlis, S. (ed.): Pharmacokinetics, psychoactive drug blood levels, and clinical response. New York: Spectrum Publications (in press)
Greenblatt, D.J., Koch-Weser, J.: Clinical pharmacokinetics. New Engl. J. Med. (in press)
Hill, J.B.: Salicylate intoxication. New Engl. J. Med.288, 1110–1113 (1973)
Kessler, K.M., Lowenthal, D.T., Warner, H., Gibson, T., Briggs, W., Reidenberg, M.M.: Quinidine elimination in patients with congestive heart failure or poor renal function. New Engl. J. Med.290, 706–709 (1974)
Koch-Wester, J.: Serum concentrations as therapeutic guides. New Engl. J. Med.287, 227–231 (1972)
—— Correlation of serum concentrations and pharmacologic effects of antiarrhythmic drugs. In: Proceedings 5th International Congress Pharmacology, San Francisco, 1972, Vol. 3, pp. 69–85, 1973 Basel: Karger 1973
—— Bioavailability of drugs. New Engl. J. Med.291, 233–237; 503–506 (1974a)
—— Clinical application of the pharmacokinetics of procainamide. Cardiovasc. Clin.6 (II, 63–75 (1974b)
—— Drug interactions in cardiovascular therapy. Amer. Heart J.90, 93–116 (1975)
——, Duhme, D.W., Greenblatt, D.J.: Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clin. Pharmacol. Ther.16, 284–287 (1974)
——, Klein, S.W.: Procainamide dosage schedules, plasma concentrations, and clinical effects. J. Amer. med. Ass.215, 1454–1460 (1971)
——, Sellers, E.M.: Drug interactions with coumarin anticoagulants. New Engl. J. Med.285, 487–498 (1971)
-- -- Binding of drugs to serum albumin. New Engl. J. Med. (in press)
Kunin, C.M.: Blood level measurements and anti-microbial agents. Clin. Pharmacol. Ther.16, 251–256 (1974)
Kutt, H., McDowell, F.: Management of epilepsy with diphenylhydantoin. J. Amer. med. Ass.203, 969–972 (1968)
—— Biochemical and genetic factors regulating Dilantin metabolism in man. Ann. N.Y. Acad. Sci.179, 704–722 (1971)
—— Pharmacodynamic and pharmacokinetic measurements of antiepileptic drugs. Clin. Pharmacol. Ther.16, 243–250 (1974)
Levy, G.: Pharmacokinetic control and clinical interpretation of steady-state blood levels of drugs. Clin. Pharmacol. Ther.16, 130–134 (1974)
Nagashima, R., O'Reilly, R.A., Levy, G.: Kinetics of pharmacologic effects in man: the anti-coagulant action of warfarin. Clin. Pharmacol. Ther.10, 22–35 (1969)
Piafsky, K.M., Ogilvie, R.I.: Dosage of theophylline in bronchial asthma. New Engl. J. Med.292, 1218–1222 (1975)
Shand, D.G.: Individualization of propranolol dosage. Med. Clin. N. Amer.58, 1063–1069 (1974)
Sheiner, L.B., Melmon, K.L., Rosenberg, B.: Instructional goals for physicians in the use of blood level data — and the contribution of computers. Clin. Pharmacol. Ther.16, 260–271 (1974)
Smith, S.E., Rawlins, M.: Variability in human drug response. London: Butterworth 1974
Smith, T.W.: Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. Amer. J. Med.58, 470–476 (1975)
Vesell, E.S. (ed.): Drug metabolism in man. Ann. N.Y. Acad. Sci.179, 1–773 (1971)
-- Factors causing interindividual variations of drug concentrations in blood. Clin. Pharmacol. Ther.16, 135–148 (1974)
Zacest, R., Koch-Weser, J.: Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin. Pharmacol. Ther.13, 420–425 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koch-Weser, J. The serum level approach to individualization of drug dosage. Eur J Clin Pharmacol 9, 1–8 (1975). https://doi.org/10.1007/BF00613423
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613423